An integrated epidemiological approach to understanding the relationship between lung health and multi-morbidity
Lead Research Organisation:
University of Bristol
Department Name: Faculty of Health Sciences
Abstract
The UK spends 70% of its healthcare budget caring for patients with multiple long-term health conditions such as dementia and chronic obstructive pulmonary disease (COPD); driven by aging populations and lifestyle factors, this figure is expected to rise. Chronic lung disease and dementia are therefore key global health challenges.
Cognition describes mental abilities, such as thinking, problem solving and remembering. Problems with cognition (cognitive dysfunction) can lead to dementia and appear very common in people with chronic lung disease. Although cognitive dysfunction may be mild and unnoticed at first, it may gradually make it more difficult for patients to perform their daily activities including taking medicines correctly. Cognitive dysfunction in chronic lung disease eventually leads to worse health, more time in hospital and shorter survival.
Individuals with chronic lung disease may be at increased risk of mild cognitive impairment (MCI) and dementia due to a combination of factors, which are both more frequent among those with lung disease and known to negatively impact on cognition (e.g., smoking and high blood pressure) or as a direct result of lung disease (e.g., low oxygen levels). However, there does seem to be a consistent link between cognitive impairment and lung disease independent of these shared factors, suggesting mechanisms specific to respiratory limitation.
The aim of this project is to determine whether chronic lung disease and cognitive impairment share a common causal pathway. It will do this by bringing together interdisciplinary expertise in epidemiology and statistics, to understand the complex interaction between genetic, developmental and early life events which determine lung health and cognition (MRC strategic aim 4).
It will also explore the relationship between early life cognition, co-morbidity and lung function trajectories using a population-based life course perspective applied to the Avon Longitudinal Study of Parents And Children (ALSPAC) cohort. (MRC strategic aim 1).
The objectives are:
a) Apply integrated genetic epidemiological methods developed by our team (2 sample Mendelian Randomisation) from large European populations to determine the causal association between lung function, cognitive impairment and risk of dementia
b) Determine if early life changes in lung function are associated with cognitive dysfunction and multi-morbidity using existing data from the ALSPAC cohort.
Benefits and applications are:
1) Help to identify modifiable risk factors and potential therapeutic targets to reduce the risk of developing dementia.
2) Advance our understanding behind the mechanisms of cognitive dysfunction in chronic lung disease.
3) Initiate the development of new ways to detect, prevent or delay progression of cognitive dysfunction in at risk populations. This will help patients to manage their treatment, maintain their health and keep out of hospital. It could also prolong survival.
4) Increase our understanding about early life risk factors for chronic lung disease and multi-morbidity
5) Inform public health policy through engagement with organisations responsible for health services delivery and management of two major long-term conditions, Chronic Obstructive Pulmonary Disease (COPD) and Dementia.
a. Awareness of cognitive dysfunction & multi-morbidity
b. Inform self-management and education
c. Keeping people with COPD and Dementia healthy at home
6) Inform and open new research questions about the interaction between long-term conditions and lung health such as cardiovascular disease, depression and diabetes.
Cognition describes mental abilities, such as thinking, problem solving and remembering. Problems with cognition (cognitive dysfunction) can lead to dementia and appear very common in people with chronic lung disease. Although cognitive dysfunction may be mild and unnoticed at first, it may gradually make it more difficult for patients to perform their daily activities including taking medicines correctly. Cognitive dysfunction in chronic lung disease eventually leads to worse health, more time in hospital and shorter survival.
Individuals with chronic lung disease may be at increased risk of mild cognitive impairment (MCI) and dementia due to a combination of factors, which are both more frequent among those with lung disease and known to negatively impact on cognition (e.g., smoking and high blood pressure) or as a direct result of lung disease (e.g., low oxygen levels). However, there does seem to be a consistent link between cognitive impairment and lung disease independent of these shared factors, suggesting mechanisms specific to respiratory limitation.
The aim of this project is to determine whether chronic lung disease and cognitive impairment share a common causal pathway. It will do this by bringing together interdisciplinary expertise in epidemiology and statistics, to understand the complex interaction between genetic, developmental and early life events which determine lung health and cognition (MRC strategic aim 4).
It will also explore the relationship between early life cognition, co-morbidity and lung function trajectories using a population-based life course perspective applied to the Avon Longitudinal Study of Parents And Children (ALSPAC) cohort. (MRC strategic aim 1).
The objectives are:
a) Apply integrated genetic epidemiological methods developed by our team (2 sample Mendelian Randomisation) from large European populations to determine the causal association between lung function, cognitive impairment and risk of dementia
b) Determine if early life changes in lung function are associated with cognitive dysfunction and multi-morbidity using existing data from the ALSPAC cohort.
Benefits and applications are:
1) Help to identify modifiable risk factors and potential therapeutic targets to reduce the risk of developing dementia.
2) Advance our understanding behind the mechanisms of cognitive dysfunction in chronic lung disease.
3) Initiate the development of new ways to detect, prevent or delay progression of cognitive dysfunction in at risk populations. This will help patients to manage their treatment, maintain their health and keep out of hospital. It could also prolong survival.
4) Increase our understanding about early life risk factors for chronic lung disease and multi-morbidity
5) Inform public health policy through engagement with organisations responsible for health services delivery and management of two major long-term conditions, Chronic Obstructive Pulmonary Disease (COPD) and Dementia.
a. Awareness of cognitive dysfunction & multi-morbidity
b. Inform self-management and education
c. Keeping people with COPD and Dementia healthy at home
6) Inform and open new research questions about the interaction between long-term conditions and lung health such as cardiovascular disease, depression and diabetes.
Technical Summary
The WHO estimates that dementia will affect 80 million people in 20 years, so there is an urgent need to identify modifiable risk factors. Mild cognitive impairment is associated with a 5-10% annual conversion rate to dementia but is considered a potentially reversible state.
3 million people live with COPD in the UK, the majority have two or more long-term health conditions, it is therefore a disease of 'multi-morbidity'. (MRC strategic theme 'living a long and healthy life')
The majority of observational studies provide evidence for an independent association between lung function and cognitive impairment. However a number of unmeasured or unaccounted confounders are likely to bias this relationship.
Objectives & Methods
Part 1: Two-sample Mendelian Randomisation using existing Genome Wide Association Studies to determine the causal association between lung function, cognitive impairment and risk of dementia
Mendelian Randomization (MR) is a form of analysis that uses genetic variants as instrumental variables. Using summary data from GWAS consortia in two-sample MR increases statistical power, particularly in relation to testing effects on binary disease outcomes, such as Alzheimer's Disease (AD) or Cognitive Impairment (CI).
Part 2: Determine if early life course lung function trajectories are associated with cognitive dysfunction and multi-morbidity using existing longitudinal data from the ALSPAC cohort.
Several measures of functional cognition and comorbidity are available from the ALSPAC clinic at 24 years. Four FEV1 trajectories from childhood to early adulthood were identified in using latent profile modelling: persistently high (4%), normal (45%), below average (44%), and persistently low (7%).
Setting the normal FEV1 trajectory as the baseline group, we will use multinomial logistic regression model to investigate the risk (betas & 95%CIs) of the membership of other trajectories per unit increase of a continuous measure of functional cognition.
3 million people live with COPD in the UK, the majority have two or more long-term health conditions, it is therefore a disease of 'multi-morbidity'. (MRC strategic theme 'living a long and healthy life')
The majority of observational studies provide evidence for an independent association between lung function and cognitive impairment. However a number of unmeasured or unaccounted confounders are likely to bias this relationship.
Objectives & Methods
Part 1: Two-sample Mendelian Randomisation using existing Genome Wide Association Studies to determine the causal association between lung function, cognitive impairment and risk of dementia
Mendelian Randomization (MR) is a form of analysis that uses genetic variants as instrumental variables. Using summary data from GWAS consortia in two-sample MR increases statistical power, particularly in relation to testing effects on binary disease outcomes, such as Alzheimer's Disease (AD) or Cognitive Impairment (CI).
Part 2: Determine if early life course lung function trajectories are associated with cognitive dysfunction and multi-morbidity using existing longitudinal data from the ALSPAC cohort.
Several measures of functional cognition and comorbidity are available from the ALSPAC clinic at 24 years. Four FEV1 trajectories from childhood to early adulthood were identified in using latent profile modelling: persistently high (4%), normal (45%), below average (44%), and persistently low (7%).
Setting the normal FEV1 trajectory as the baseline group, we will use multinomial logistic regression model to investigate the risk (betas & 95%CIs) of the membership of other trajectories per unit increase of a continuous measure of functional cognition.
Planned Impact
This research project has the potential for far reaching impact. It aims to help identify modifiable risk factors and potential treatments to reduce the risk of developing dementia and advance our understanding of the mechanisms that cause cognitive dysfunction and multi-morbidity in chronic lung disease.
Ultimately this should allow development of new ways to detect, prevent or delay progression of cognitive dysfunction in chronic lung disease, thereby helping patients to manage their treatment, maintain their health and keep out of hospital. It could also prolong survival.
National & International policy makers:
There will be policy implications relating to findings that may lead to improved recognition or enhanced screening for dementia and multi-morbidity in high-risk populations (such as those with chronic lung disease). In addition this could lead to improved healthcare advice and public health interventions to lessen the risk of adverse outcomes. Although these are likely to include tobacco control and cardiovascular risk reduction there are other modifiable factors of potential importance, including diet, obesity and physical activity that are not currently recognised as adverse factors for future lung health.
Health Professionals & Commissioners:
Clinicians including GPs, specialists in respiratory & elderly medicine, and memory clinics will benefit from an increased awareness and understanding about early life risk factors for chronic lung disease and multi-morbidity and dementia.
It also has implications for the organisation of health services delivery. Specifically, these include regional clinical commissioning groups (CCG) and NHS England who are working on sustainability and transformations plans (STPs) in key themes of respiratory, dementia and long-term conditions such as COPD and Dementia.
This work on cognition and co-morbidity in chronic lung disease will also benefit front line clinical staff to develop new ways of supporting people with COPD to self-manage and deliver effective education.
Charities and research funding bodies:
This project addresses the key global health challenges highlighted by the NIHR, MRC and British Lung Foundation. It will allow these funding bodies to prioritise and allocate resources appropriately for future research and improve communications and support for patients and carers who may be affected by chronic lung disease and dementia.
The general public:
3 million people live with COPD in the UK but only 1 million have been diagnosed, meaning many miss out on the opportunity for the help and support of healthcare professionals. The wider public will benefit from a raised awareness of the increasing health challenge and implications of living longer with multiple health conditions. It will allow people to consider the lifestyle changes that they may be able to take in order to protect themselves. The findings could also be used to help people with COPD and Dementia and their carers better understand what is needed to stay healthy and manage their long terms conditions to stay in their own home
We will use 'PolicyBristol', a dedicated policy unit working with researchers to enhance the influence and impact of research from across the University of Bristol on policy and practice at the local, national and international level. On a practical level this is achieved through Policy Briefings and Reports, Events such as a policy workshop or seminar and Communications: including via social media platforms such as blogs and Twitter
Ultimately this should allow development of new ways to detect, prevent or delay progression of cognitive dysfunction in chronic lung disease, thereby helping patients to manage their treatment, maintain their health and keep out of hospital. It could also prolong survival.
National & International policy makers:
There will be policy implications relating to findings that may lead to improved recognition or enhanced screening for dementia and multi-morbidity in high-risk populations (such as those with chronic lung disease). In addition this could lead to improved healthcare advice and public health interventions to lessen the risk of adverse outcomes. Although these are likely to include tobacco control and cardiovascular risk reduction there are other modifiable factors of potential importance, including diet, obesity and physical activity that are not currently recognised as adverse factors for future lung health.
Health Professionals & Commissioners:
Clinicians including GPs, specialists in respiratory & elderly medicine, and memory clinics will benefit from an increased awareness and understanding about early life risk factors for chronic lung disease and multi-morbidity and dementia.
It also has implications for the organisation of health services delivery. Specifically, these include regional clinical commissioning groups (CCG) and NHS England who are working on sustainability and transformations plans (STPs) in key themes of respiratory, dementia and long-term conditions such as COPD and Dementia.
This work on cognition and co-morbidity in chronic lung disease will also benefit front line clinical staff to develop new ways of supporting people with COPD to self-manage and deliver effective education.
Charities and research funding bodies:
This project addresses the key global health challenges highlighted by the NIHR, MRC and British Lung Foundation. It will allow these funding bodies to prioritise and allocate resources appropriately for future research and improve communications and support for patients and carers who may be affected by chronic lung disease and dementia.
The general public:
3 million people live with COPD in the UK but only 1 million have been diagnosed, meaning many miss out on the opportunity for the help and support of healthcare professionals. The wider public will benefit from a raised awareness of the increasing health challenge and implications of living longer with multiple health conditions. It will allow people to consider the lifestyle changes that they may be able to take in order to protect themselves. The findings could also be used to help people with COPD and Dementia and their carers better understand what is needed to stay healthy and manage their long terms conditions to stay in their own home
We will use 'PolicyBristol', a dedicated policy unit working with researchers to enhance the influence and impact of research from across the University of Bristol on policy and practice at the local, national and international level. On a practical level this is achieved through Policy Briefings and Reports, Events such as a policy workshop or seminar and Communications: including via social media platforms such as blogs and Twitter
Organisations
Publications
Arnold DT
(2021)
Standard pleural interventions are not high-risk aerosol generating procedures.
in The European respiratory journal
Elwenspoek MM
(2021)
Effects of an integrated respiratory service on Chronic Obstructive Pulmonary Disease hospital admissions in England: An interrupted time series analysis.
in Journal of health services research & policy
Golding J
(2023)
A history of asthma may be associated with grandparents' exposures to stress and cigarette smoking.
in Frontiers in toxicology
Grenville J
(2023)
Lung function and cognitive ability in children: a UK birth cohort study.
in BMJ open respiratory research
Grenville J
(2022)
Lung function and cognitive ability in children: a UK birth cohort study
Description | UK Infection Prevention & Control |
Geographic Reach | National |
Policy Influence Type | Citation in other policy documents |
Impact | My work with UKRI funded AERATOR study has pioneered translation of aerosol sciences in respiratory medicine. Results have been communicated to the NIHR Task and Finishing Group, which feeds directly to SAGE and has informed changes in national guidelines including the management of patients with respiratory failure and lung function testing. I am working with UK infection protection and control (IPC) cell updating the list of aerosol generating procedures. Our findings on the dangers of cough to healthcare works had front page coverage in The Guardian and global media outlets and acts as a case study for Bristol NIHR BRC bid. The British Thoracic & Primary Care Respiratory Societies are using this data to advise on safe resumption of NHS services. |
URL | https://www.england.nhs.uk/wp-content/uploads/2022/04/C1632_rapid-review-of-aerosol-generating-proce... |
Description | AERosolisation And Transmission Of SARS-CoV-2 in Healthcare Settings (AERATOR) |
Amount | £622,785 (GBP) |
Funding ID | COV0333 |
Organisation | National Institute for Health Research |
Sector | Public |
Country | United Kingdom |
Start | 07/2020 |
End | 08/2023 |
Description | Bristol Biomedical Research Centre |
Amount | £12,000,000 (GBP) |
Organisation | National Institute for Health Research |
Sector | Public |
Country | United Kingdom |
Start |
Description | Bristol Evaluation of novel Airways diagnostics, Therapeutics & healthcare OutcomEs (BREATHE study) |
Amount | £20,000 (GBP) |
Organisation | Southmead Hospital Charity |
Sector | Public |
Country | United Kingdom |
Start | 01/2022 |
End | 01/2023 |
Description | CONTENTed study: Characterisation Of Neuroimaging and wellbeing over Time in severe EosiNophilic asthma Treated with mepolizumab. |
Amount | £499,000 (GBP) |
Organisation | GlaxoSmithKline (GSK) |
Sector | Private |
Country | Global |
Start | 12/2023 |
End | 12/2025 |
Description | DISCOVER DIagnostic and Severity markers of COVID-19 to Enable Rapid triage study |
Amount | £152,000 (GBP) |
Organisation | Southmead Hospital Charity |
Sector | Public |
Country | United Kingdom |
Start |
Description | Digital health champions and uptake of myCOPD apps |
Amount | £194,000 (GBP) |
Organisation | NHS Digital |
Sector | Public |
Country | United Kingdom |
Start | 11/2021 |
End | 09/2022 |
Description | Digital spirometry in patients with respiratory symptoms - RCT. Springboard grant |
Amount | £20,000 (GBP) |
Organisation | Southmead Hospital Charity |
Sector | Public |
Country | United Kingdom |
Start | 06/2021 |
End | 10/2022 |
Description | Improving COPD outcomes through digitally enhanced care pathways SBRI Healthcare Phase 3 |
Amount | £499,000 (GBP) |
Organisation | SBRI Healthcare |
Sector | Private |
Country | United Kingdom |
Start |
Description | RAPID study Rescue packs post-discharge in COPD (£2.8M) 2023-2027 NIHR Health Technology Assessment (HTA) Programme |
Amount | £2,800,000 (GBP) |
Organisation | National Institute for Health Research |
Sector | Public |
Country | United Kingdom |
Start |
Description | Religious belief, health and disease: II. The follow-up and data analysis, |
Amount | £8,000,000 (GBP) |
Organisation | The John Templeton Foundation |
Sector | Academic/University |
Country | United States |
Start |
Description | Understanding the origins of chronic lung disease |
Amount | £30,000 (GGP) |
Organisation | Chiesi |
Sector | Private |
Country | Italy |
Start | 11/2021 |
End | 11/2024 |
Description | Understanding the origins of chronic lung disease & the impact of COVID-19 |
Amount | £191,000 (GBP) |
Organisation | Southmead Hospital Charity |
Sector | Public |
Country | United Kingdom |
Start | 11/2021 |
End | 11/2024 |
Description | AERosolisation And Transmission Of SARS-CoV-2 in Healthcare Settings (AERATOR) |
Organisation | University of Bristol |
Department | School of Chemistry |
Country | United Kingdom |
Sector | Academic/University |
PI Contribution | I am a Co applicant and workpackage lead. Design, deliver, write up and disseminate respiratory based aerosol studies |
Collaborator Contribution | Led by Prof Reid, world learning aerosol scientists in the measurement and analysis of aerosols |
Impact | Multidisciplinary collaboration - aerosol scientist, clinicians, AHP Risk and mitigation of aerosolisation from lung function testing: results from the AERATOR study. Sadiyah Sheikh, Fergus W Hamilton, George Nava, Florence Gregson, David T Arnold, Colleen Riley, Jules Brown, AERATOR Group, Bryan Bzdek, Jonathan Reid, Nick Maskell, James W Dodd medRxiv 2021.03.06.21253033; doi: https://doi.org/10.1101/2021.03.06.21253033 Aerosol emission from the respiratory tract: an analysis of relative risks from oxygen delivery systems F Hamilton, F Gregson, D Arnold, S Sheikh, K Ward, J Brown, E Moran, C White, A Morley, AERATOR group, B Bzdek, J Reid, N Maskell, JW Dodd medRxiv 2021.01.29.21250552; doi: https://doi.org/10.1101/2021.01.29.21250552 Add to Selected Citations |
Start Year | 2020 |
Description | ALSPAC Respiratory theme lead |
Organisation | University of Bristol |
Department | Avon Longitudinal Study of Parents and Children (ALSPAC) |
Country | United Kingdom |
Sector | Academic/University |
PI Contribution | I am clinical advisory board chair for ALSPAC study, this body advises the study PI Nic Timpson on clinical measures undertaken in ALSPAC. With Raquel Granell (respiratory statistician) we lead the respiratory theme within ALSPAC. I supervise a PhD student using integrative epidemiology methods to explore the causal relationship between lung function, COPD and comorbid cognitive and vascular disease. We are also looking at the psychological aspect of Asthma in ALSPAC |
Collaborator Contribution | George Davey Smith is Co app on MRC CARP award with Raquel Granell, they are also co supervisors of my PhD student. I work with Nic Timpson on grant submission for respiratory measures in ALSPAC |
Impact | MRC CARP award PhD studentship MRC PSMB bid 2 papers in write up |
Start Year | 2019 |
Description | Antibiotics of aLRTI in Asthma |
Organisation | University of Bristol |
Department | School of Social and Community Medicine |
Country | United Kingdom |
Sector | Academic/University |
PI Contribution | Clinical expert and Co applicant |
Collaborator Contribution | HTA grant development ongoing |
Impact | Ongoing |
Start Year | 2023 |
Description | CC16 and lung development ALSPAC and Tucson study |
Organisation | University of Arizona Medical Center |
Country | United States |
Sector | Hospitals |
PI Contribution | NIH renewal |
Collaborator Contribution | Clinical co applicant PI ALSPAC |
Impact | Ongoing |
Start Year | 2024 |
Description | MRC integrative epidemiology unit. University of Bristol |
Organisation | University of Bristol |
Department | MRC Integrative Epidemiology Unit |
Country | United Kingdom |
Sector | Academic/University |
PI Contribution | Clinical academic partner. Research theme on lung function and causal associations with cognition and multi morbidity |
Collaborator Contribution | Expertise, methodology, access to people and training |
Impact | Application to MRC CARP -successful Clinical research fellow PhD project with peer review publications in high impact journals (see linked publications) Conference abstracts of findings New collaborations and research grants in progress replication GWAS of preserved ratio impaired impaired spirometry (CHARGE consortium) Submission to MRC PSMB research grant for collection and completion of lung health measures at age 30 in Avon Longitudinal Study of Parents and Children (ALSPAC) |
Start Year | 2020 |
Description | Rescue pack in AECOPD |
Organisation | Kings Health Partners |
Country | United Kingdom |
Sector | Hospitals |
PI Contribution | NIHR funded HTA grant RCT of rescue pack in COPD |
Collaborator Contribution | Co applicant |
Impact | Project set up |
Start Year | 2023 |
Description | University of Hull - AI/Digital engineering |
Organisation | University of Hull |
Department | School of Engineering |
Country | United Kingdom |
Sector | Academic/University |
PI Contribution | Clinical lead and co applicant on NIHR i4i application AI measurement of indoor air pollution in asthma |
Collaborator Contribution | Engineers and project lead |
Impact | Ongoing grant development |
Start Year | 2023 |
Description | carotid body sensitisation and breathlessness in LongCOVID |
Organisation | Bristol Heart Institute |
Country | United Kingdom |
Sector | Hospitals |
PI Contribution | Expert clinical co applicant |
Collaborator Contribution | Project lead |
Impact | MRC grant co applicant |
Start Year | 2023 |
Description | my M health COPD exacerbation prediction |
Organisation | My mhealth Limited |
Country | United Kingdom |
Sector | Public |
PI Contribution | Chief investigator, clinical lead and primary PhD supervisor Interdisciplinary collaboration with Engineers and digital technology company to use machine learning approach to exacerbation prediction modelling in COPD |
Collaborator Contribution | Data for analytics, contribution to PhD fees, co-applicant, data interpretation |
Impact | NHS Digital Health Partnership Award SBRI Phase 3 grant 2 international abstracts PhD Studentship |
Start Year | 2021 |
Description | Public appeal for engagement with COVID-19 study for participants of ASLPAC cohort |
Form Of Engagement Activity | Engagement focused website, blog or social media channel |
Part Of Official Scheme? | No |
Geographic Reach | Regional |
Primary Audience | Public/other audiences |
Results and Impact | In support of COVID-19 questionnaire to be emailed to over 10,000 participants I was asked to record a short video to share on social media/our website . "As a respiratory/chest consultant at Southmead I know how important the Children of the 90s health study is - right now - in the fight against the Coronavirus. If you are a participant in the study please find 10 minutes to fill in this new Coronavirus questionnaire. Its findings will tell the government how many participants have already had the virus, even with very mild symptoms. And this will help us to stop this deadly infection more quickly. Thanks for doing your bit to help the NHS! " "If you were born in Bristol between April 1991-December 1992 you could be part of the study. Please text 07772 909090 or visit childrenofthe90s.ac.uk for more information. Your help will make a real difference, thank you" Feedback on impact from ALSPAC comms team Hi James I just wanted to thank you for making the film clips. You might not be aware but we have had a big response to the films on social media. The second video reached 13,700+ people and was shared 102 times, while the first video was shared 113 times, these are much bigger than the normal reach for our posts. What's more, I'm sure that the films directly lead to participants re-engaging in the study as we've had a big spike in numbers getting back in touch in April. Some haven't been involved since they were children and certainly fall into our 'disengaged' category. At last count we are at over 5,000 responses to the questionnaire, which is great news. On the back of this, we would ideally like to use a quote from you in our local media outreach - would you be happy for this to be included in a press release - going out to local Bristol media this week? Article here: https://www.bristolpost.co.uk/news/bristol-news/6000-people-take-part-groundbreaking-4107341 |
Year(s) Of Engagement Activity | 2020 |
URL | https://www.facebook.com/login/?next=https%3A%2F%2Fwww.facebook.com%2Fchildrenofthe90s%2Fposts%2F101... |